Mcnamara Financial Services Exits Position in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Mcnamara Financial Services has sold out all of its stake in Gilead Sciences during the most recent quarter, according to the disclosure filed by the company on Apr 13, 2016 with the SEC. The investment management company has sold out 3,220 shares of Gilead Sciences which is valued at $316,494.

Gilead Sciences opened for trading at $98.17 and hit $99.73 on the upside on Monday, eventually ending the session at $99.2, with a gain of 0.93% or 0.91 points. The heightened volatility saw the trading volume jump to 80,67,829 shares. Company has a market cap of $135,591 M.

Other Hedge Funds, Including , F&v Capital Management reduced its stake in GILD by selling 710 shares or 1.15% in the most recent quarter. The Hedge Fund company now holds 61,230 shares of GILD which is valued at $6,018,297. Gilead Sciences makes up approx 4.67% of F&v Capital Management’s portfolio. Capital Asset Advisory Services added GILD to its portfolio by purchasing 18,393 company shares during the most recent quarter which is valued at $1,807,848. Gilead Sciences makes up approx 2.06% of Capital Asset Advisory Services’s portfolio.Capstone Asset Management Co reduced its stake in GILD by selling 943 shares or 0.75% in the most recent quarter. The Hedge Fund company now holds 124,868 shares of GILD which is valued at $12,273,276. Gilead Sciences makes up approx 0.35% of Capstone Asset Management Co’s portfolio.Nexus Investment Management boosted its stake in GILD in the latest quarter, The investment management firm added 8,300 additional shares and now holds a total of 198,850 shares of Gilead Sciences which is valued at $19,055,796. Gilead Sciences makes up approx 3.63% of Nexus Investment Management’s portfolio. Sunnymeath Asset Management added GILD to its portfolio by purchasing 850 company shares during the most recent quarter which is valued at $81,456. Gilead Sciences makes up approx 0.13% of Sunnymeath Asset Management’s portfolio.

On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.